Premium Nahrungsergänzungsmittel | artgerecht

Galectin 3: Biomarker for Heart Failure & Fibrosis

Galectin 3 is a naturally occurring protein involved in inflammation, fibrosis, and heart disease. It is widely used as a biomarker for risk assessment in heart failure and other conditions.

Regular tips about health Regular tips about health

Things worth knowing about "Galectin 3"

Galectin 3 is a naturally occurring protein involved in inflammation, fibrosis, and heart disease. It is widely used as a biomarker for risk assessment in heart failure and other conditions.

What is Galectin 3?

Galectin 3 is a protein belonging to the lectin family – a group of molecules that bind to carbohydrate (sugar) chains on cell surfaces. It is produced and secreted by immune cells, connective tissue cells, and tumor cells. Galectin 3 plays multiple roles in the body, including regulating immune and inflammatory responses, promoting tissue scarring (fibrosis), and influencing cell survival and cancer progression.

Biological Functions

Galectin 3 carries out several important functions in the human body:

Immune regulation: It controls the activation and movement of immune cells such as macrophages and neutrophils, thereby shaping the course of inflammatory responses.
Fibrosis promotion: Galectin 3 activates fibroblasts (cells that produce connective tissue) and drives the excessive deposition of collagen in organs – a key mechanism in the development of fibrosis (tissue hardening and scarring).
Cell proliferation and apoptosis: The protein influences whether cells grow or die, which is particularly relevant in cancer biology.
Cell adhesion and migration: Galectin 3 promotes cell attachment and movement through tissues, contributing to both inflammation and cancer metastasis.

Clinical Importance as a Biomarker

Elevated galectin 3 levels in the blood are associated with several diseases. As a biomarker – a measurable biological indicator – galectin 3 provides valuable diagnostic and prognostic information across multiple conditions.

Heart Failure

Galectin 3 is an established biomarker in heart failure. Elevated levels reflect increased fibrosis of cardiac tissue and are linked to worse clinical outcomes, higher rates of hospitalization, and increased mortality. The galectin 3 test is approved by the FDA and in Europe for risk stratification in patients with heart failure.

Fibrotic Diseases

Since galectin 3 is directly involved in fibrosis, elevated levels are also observed in a range of fibrotic conditions, including:

Liver fibrosis and cirrhosis
Kidney fibrosis (chronic kidney disease)
Pulmonary fibrosis
Cardiac fibrosis

Cancer

Galectin 3 promotes tumor cell survival, facilitates metastasis, and contributes to resistance against chemotherapy. Elevated levels have been detected in various cancer types, including breast, colorectal, thyroid, and prostate cancer.

Inflammatory and Autoimmune Diseases

Galectin 3 also plays a role in chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease, where it modulates immune cell activity and drives sustained inflammation.

Diagnosis: The Galectin 3 Test

Galectin 3 levels are measured using a simple blood test. The test is typically performed using an ELISA (enzyme-linked immunosorbent assay) and provides quantitative values in ng/ml. Reference ranges may vary by laboratory. Elevated values are interpreted in combination with other clinical findings and biomarkers (e.g., BNP or NT-proBNP in heart failure).

Therapeutic Approaches: Galectin 3 Inhibition

Given its central role in fibrosis and cancer, galectin 3 is an active target for novel therapies. Several approaches to inhibiting galectin 3 are currently being investigated:

Modified Citrus Pectin (MCP): A natural plant-derived compound that acts as a galectin 3 inhibitor and is being studied in clinical trials.
Synthetic inhibitors: Various small molecules designed to block the carbohydrate-binding site of galectin 3 are in active clinical development.
Antibody-based therapies: Monoclonal antibodies targeting galectin 3 are being explored as potential treatment options in cancer and fibrotic diseases.

References

Yancy CW et al. - 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 62(16), 2013.
Bhaskaran M, Bhaskaran S. - Galectin-3 in Fibrosis: Mechanisms and Therapeutic Opportunities. Frontiers in Pharmacology, 2021.
Liu FT, Rabinovich GA. - Galectins as modulators of tumour progression. Nature Reviews Cancer, 5(1), 2005.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.